glp 1 coverage canada Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss Canada first in G7 to

The next generation of regimens may involve combining GLP-1 or dual GIP/GLP-1 receptor agonists with other nutrient-based hormone receptor agonists or antagonists that offer equal or greater effectiveness with fewer gastrointestinal adverse effects

Rotating injection sites and proper technique can minimise these effects

Only a small number of GLP-1 medications are FDA-approved specifically for weight lossothers are typically used for type 2 diabetes management

Lexapro can dilate the pupils and trigger an angle-closure glaucoma attack

For blood glucose control in patients with type 2 diabetes, initial effects can often be observed within the first 1-2 weeks of treatment as the medication begins influencing insulin and glucagon secretion

JCO Clin